Alx Oncology Holdings (ALXO) Non-Current Debt (2019 - 2026)

Alx Oncology Holdings (ALXO) has 7 years of Non-Current Debt data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 59.97% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 59.97% YoY), and the FY2025 full-year result was $4.5 million, down 52.14% from the prior year.
• Non-Current Debt fell to $3.3 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $9.8 million in Q3 2024 to a low of $3.3 million in Q1 2026.
• A 5-year average of $8.2 million and a median of $9.5 million in 2023 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt increased 2.72% in 2024 and sank 59.97% in 2026, its largest moves.
• Tracing ALXO's Non-Current Debt over 5 years: stood at $9.4 million in 2022, then rose by 2.66% to $9.6 million in 2023, then declined by 1.76% to $9.5 million in 2024, then plunged by 52.14% to $4.5 million in 2025, then slipped by 27.29% to $3.3 million in 2026.
• Business Quant data shows ALXO's Non-Current Debt at $3.3 million in Q1 2026, $4.5 million in Q4 2025, and $5.8 million in Q3 2025.